Clinical trial NCT03682419: Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
Official title: Evaluation of the Precision and Accuracy of International Normalised Ratio (INR) Measurements as Assessed by the LumiraDx Instrument in a Professional Point of Care Setting With Multiple Operators
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Deep Vein Thrombosis
Atrial Fibrillation
Post-Myocardial Infarction Syndrome
Pulmonary Embolism
Artificial Heart Device User
Thrombophilia
Antiphospholipid Syndrome
Lead sponsor: LumiraDx UK Limited
Sponsor class: INDUSTRY
First posted: 2018-09-24
Enrollment: 420
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: A performance evaluation study.
Primary purpose: DIAGNOSTIC

Brief summary: Comparison of capillary whole blood INR determined by LumiraDx Instrument to venous plasma INR determined by laboratory reference method (IL ACL ELITE PRO) for method comparison and assessment of accuracy and bias by regression analysis and other analytical methods.

Detailed description: A performance evaluation study designed to assess the precision and accuracy of the LumiraDx Instrument, a point of care in vitro diagnostic system employing a portable diagnostic meter in conjunction with single use analyte test strips, for the quantitative determination of Prothrombin Time expressed as International Normalised Ratio (INR), as sampled from individuals evaluated for INR at the point of care (POC).

The accuracy of the LumiraDx Instrument INR results will be assessed by, in the first instance, comparison to the INR results obtained from the same individuals as analysed by trained laboratory professionals using the paired venous plasma samples in the reference device IL ACL ELITE PRO Coagulation Analyzer. The accuracy of INR measurements of capillary whole blood across the range of haematocrit (25% - 55%) will be assessed using paired haematocrit results obtained from the HemoCue Hb 201+ on venous whole blood. The results of these evaluations are intended to be used for regulatory filings for the LumiraDx Instrument and LumiraDx INR test as an in vitro diagnostic test in the European Union (EU) and other relevant geographies. For information only, the accuracy of the LumiraDx Instrument INR Test will also be assessed by comparison to INR results from an alternative point of care instrument, the Roche Coaguchek PRO II.

Adult males and females currently in receipt of vitamin K antagonist therapy will be included on the study. Approximately 500 subjects will be recruited to ensure that sufficient suitable subjects are enrolled and to allow for a small level of exclusions. The power calculation as well as recommendations of the FDA CLIA Waiver Guidance document (1) requires a minimum of 360 valid subjects in total (inclusive of non-therapy subset). A subsection of the subject population (\~50 subjects) will consist of adult males and females who fulfil all other study inclusion criteria but are not in receipt of vitamin K antagonist therapy. This will be done in order to test the lower measurement limit of the LumiraDx Instrument INR test. At the end of the study the Healthcare Professional will be asked to complete a User Acceptability Questionnaire which is intended to assess the acceptability of the LumiraDx INR system in terms of ease of use.

Eligibility criteria: Inclusion Criteria - VKA Therapy Subjects:

* Persons \>18 years of age
* Willing and able to provide written informed consent and comply with study procedures
* Currently prescribed vitamin K antagonist therapy
* Deemed medically appropriate for study participation by the Investigator

Exclusion Criteria - VKA Therapy Subjects:

* Persons \<18 years of age
* Subject has previously participated in this study
* Subject is within 4 weeks of first prescription of vitamin K antagonist therapy
* Confirmed or suspected pregnancy
* Unwilling or unable to provide written informed consent and comply with study procedures
* Vulnerable populations deemed inappropriate for study by the Investigator
* Deemed medically inappropriate for study by the Investigator (i.e. patients with a known inherited \[e.g. haemophilia or von Willebrand's disease\] or acquired \[e.g. liver cirrhosis\] condition likely to be associated with a coagulopathy; or patients receiving non-VKA anticoagulant medications)

Inclusion Criteria - Non-VKA Therapy Subjects:

* Persons \>18 years of age
* Willing and able to provide written informed consent and comply with study procedures
* Deemed medically appropriate for study participation by the Investigator

Exclusion Criteria - Non-VKA Therapy Subjects:

* Persons \<18 years of age
* Subject has previously participated in this study
* Confirmed or suspected pregnancy
* Unwilling or unable to provide written informed consent and comply with study procedures
* Vulnerable populations deemed inappropriate for study by the Investigator
* Any persons deemed medically inappropriate for study by the Investigator

Primary outcomes:
measure: To determine the clinical performance of the LumiraDx instrument
timeFrame: 8 weeks
Secondary outcomes:
measure: To determine the accuracy of the LumiraDx instrument
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Glasgow
country: United Kingdom
facility: Glasgow Royal Infirmary Clinical Research Facility
city: Glasgow
country: United Kingdom
facility: Golden Jubilee National Hospital
city: Wishaw
country: United Kingdom
facility: Wishaw General Hospital, NHS Lanarkshire
Study officials:
affiliation: Consultant Haematologist
name: Robert C Tait, BSc (Hons)
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tait RC, Hung A, Gardner RS. Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619890423. doi: 10.1177/1076029619890423.